Mixed Results for Adjuvant Pembro in Endometrial Cancer
Adding adjuvant pembrolizumab to chemotherapy only led to a benefit in patients with mismatch repair-deficient high-risk endometrial cancers, a phase 3 trial found.
Medscape Medical News
source https://www.medscape.com/viewarticle/adjuvant-pembrolizumab-endometrial-cancer-disappointing-yet-2024a1000h0l?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/adjuvant-pembrolizumab-endometrial-cancer-disappointing-yet-2024a1000h0l?src=rss
Comments
Post a Comment